Categories: Health

Live tumor imaging company Elephas garners $55M

Spread the love

Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. 

Advertisements

Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the round. 

Existing investors Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital and ARCH Ventures also participated in the raise. 

WHAT IT DOES

Advertisements
Advertisements

Elephas is developing a diagnostics platform to predict a patient’s response to immunotherapy using metabolic imaging. 

Advertisements

Immunotherapy is a therapeutic approach that helps the immune system fight cancer. 

The Wisconsin-based company analyzes a tumor’s architecture via a patient biopsy and treats it with potential therapies to determine treatment response. 

Advertisements

“The Elephas platform holds immense promise to address a critical unmet need in predicting response to immunotherapy,” Venture Investors Health Fund’s Paul Weiss said in a statement. “We are excited to work side by side with the company to pioneer a new diagnostic era for immunotherapy that will improve both access to therapy and outcomes for patients.”

MARKET SNAPSHOT 

Advertisements

Immunotherapy is used to treat various types of cancers. Still, chemotherapy, radiation therapy and surgery are the more widely used forms of treatment, according to the National Cancer Institute

Another company using emerging technologies to aid in the fight against cancer includes GE Healthcare, which announced a strategic partnership with Mayo Clinic in September, dubbed the Strategic Collaboration for Innovation in Medical Imaging and Theranostics. The collaboration focuses on advancing research and product development focusing on precision care, AI and theranostics.

Theranostics is an emerging technology and a form of precision medicine that fuses imaging technology with therapeutic agents to pinpoint and target cancer cells for destruction.

In November, GE Healthcare announced another collaboration, this time with Grand Rapids-based cancer treatment center BAMF Health, to advance the adoption of theranostics.



Source link

Advertisements
Jessica Hagen

Share
Published by
Jessica Hagen

Recent Posts

Growing Threats Targeting OT Organizations

Nearly one-third (31%) of OT organizations reported more than six intrusions in the last year,…

5 mins ago

Everyone can see the people eating dinner – but you have 20/20 vision & a high IQ if you spot the robots in 12 seconds

THIS mind-boggling optical illusion has puzzle fanatics stumped and struggling to find the answer -…

28 mins ago

Abra bet leads all winners in Binibining Pilipinas 2024 pageant

Myrna Esguerra from Abra crowned as the Binibining Pilipinas International 2024 after answering a question…

30 mins ago

France ‘pushed into the hands of the far-left’ says leader of far-right | Elections

NewsFeedFrance’s leader of the far-right National Rally says a ‘dishonourable alliance’ prevented his party from…

33 mins ago

Unlocking New Dimensions of Quantum Communication

Figure 1. The signal photon, manipulated by the integrated photonic circuit, creates a 4D qudit…

42 mins ago

New Labour government must reintroduce Tobacco and Vapes Bill in next parliamentary session

Nick Hopkinson chair and professor, Sarah Woolnough chief executive, Jeanette Dickson chair of council, Mike…

51 mins ago

This website uses cookies.